Have a personal or library account? Click to login
A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination Cover

A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination

Open Access
|Sep 2022

Abstract

Background: BNT162b2 is a widely used mRNA COVID-19 vaccine for which 8.2% of participants above the age of 56 years have reported diarrhea as an adverse event. This case report highlights the possibility of eosinophilic colitis in post-vaccination diarrhea.

Case report: A 72-year-old male patient presented with generalized colicky abdominal pain and acute diarrhea after receiving the first dose of the BNT162b2 vaccine. Laboratory examination revealed peripheral blood eosinophilia with cecal and ascending colon mucosal eosinophilia with 100–130 cells/HPF and eosinophilic cryptitis. The patient’s symptoms and eosinophilia resolved spontaneously and did not recur after the second dose of vaccination. More research is needed to confirm eosinophilic colitis as a possible vaccine adverse reaction.

DOI: https://doi.org/10.2478/jim-2022-0009 | Journal eISSN: 2501-8132 | Journal ISSN: 2501-5974
Language: English
Page range: 44 - 46
Submitted on: May 20, 2022
Accepted on: Jun 27, 2022
Published on: Sep 21, 2022
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Selva Yuwaraj Vadioaloo, Mazura Mohamed Zahidi, Phei Oon Tan, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.